Mesirow Financial Investment Management Inc. Buys New Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Mesirow Financial Investment Management Inc. purchased a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the third quarter, Holdings Channel.com reports. The institutional investor purchased 16,350 shares of the company’s stock, valued at approximately $372,000.

A number of other institutional investors have also recently bought and sold shares of the business. Maverick Capital Ltd. grew its stake in shares of Viridian Therapeutics by 22.9% in the 2nd quarter. Maverick Capital Ltd. now owns 3,307,945 shares of the company’s stock valued at $43,036,000 after purchasing an additional 615,531 shares during the period. Vanguard Group Inc. boosted its stake in Viridian Therapeutics by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock valued at $56,632,000 after buying an additional 233,331 shares in the last quarter. Novo Holdings A S grew its position in Viridian Therapeutics by 19.3% in the third quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock valued at $54,259,000 after acquiring an additional 385,000 shares during the period. Candriam S.C.A. raised its stake in Viridian Therapeutics by 167.8% during the second quarter. Candriam S.C.A. now owns 749,804 shares of the company’s stock worth $9,754,000 after acquiring an additional 469,804 shares in the last quarter. Finally, Millennium Management LLC lifted its holdings in shares of Viridian Therapeutics by 1,014.7% during the second quarter. Millennium Management LLC now owns 228,182 shares of the company’s stock valued at $2,969,000 after acquiring an additional 207,711 shares during the period.

Viridian Therapeutics Stock Down 12.8 %

Shares of NASDAQ VRDN opened at $22.43 on Wednesday. The company has a current ratio of 15.82, a quick ratio of 15.82 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $1.43 billion, a PE ratio of -5.33 and a beta of 1.10. The firm’s 50-day moving average is $22.04 and its 200-day moving average is $16.78. Viridian Therapeutics, Inc. has a 1 year low of $11.40 and a 1 year high of $27.20.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on VRDN. Wedbush reaffirmed an “outperform” rating and issued a $42.00 target price on shares of Viridian Therapeutics in a report on Monday, July 29th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $44.00 price objective on shares of Viridian Therapeutics in a research note on Thursday, September 19th. The Goldman Sachs Group lifted their target price on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. BTIG Research increased their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research report on Thursday, September 26th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Viridian Therapeutics in a report on Tuesday, September 10th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $35.80.

Insider Buying and Selling at Viridian Therapeutics

In related news, CEO Stephen F. Mahoney purchased 21,400 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were bought at an average price of $23.33 per share, with a total value of $499,262.00. Following the purchase, the chief executive officer now directly owns 21,400 shares in the company, valued at $499,262. The acquisition was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Stephen F. Mahoney purchased 21,400 shares of the stock in a transaction dated Friday, September 27th. The stock was bought at an average cost of $23.33 per share, with a total value of $499,262.00. Following the purchase, the chief executive officer now directly owns 21,400 shares in the company, valued at $499,262. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, COO Thomas W. Beetham acquired 5,000 shares of Viridian Therapeutics stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the purchase, the chief operating officer now directly owns 6,000 shares in the company, valued at $140,460. The trade was a 500.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 1,626,400 shares of company stock valued at $30,616,312. 0.65% of the stock is currently owned by insiders.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.